Spero Therapeutics, Inc. Foreign Currency Transaction Gain (Loss), before Tax
Spero Therapeutics, Inc. (SPRO) reported Foreign Currency Transaction Gain (Loss), before Tax of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2024-03-13
- Spero Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2023-12-31 was $0.00.
- Spero Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2023-09-30 was $0.00.
- Spero Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2023-06-30 was $0.00.
- Spero Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. foreign currency transaction gain (loss), before tax for fiscal 2023 was $0.00.
- Spero Therapeutics, Inc. foreign currency transaction gain (loss), before tax for fiscal 2022 was -$10.00K.
- Spero Therapeutics, Inc. foreign currency transaction gain (loss), before tax for fiscal 2021 was -$13.00K, a 103.94% decline from fiscal 2020.
- Spero Therapeutics, Inc. foreign currency transaction gain (loss), before tax for fiscal 2020 was $330.00K, a 1733.33% increase from fiscal 2019.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $0.00 10-K · filed 2024-03-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | -$2.00K derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | -$2.00K derived: sum of 3 quarters · filed 2024-03-13 | -$3.00K derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | -$2.00K derived: sum of 2 quarters · filed 2024-03-13 | -$3.00K derived: sum of 3 quarters · filed 2024-03-13 | -$21.00K derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$3.00K derived: sum of 2 quarters · filed 2024-03-13 | -$21.00K derived: sum of 3 quarters · filed 2024-03-13 | -$10.00K 10-K · filed 2024-03-13 |
| 2022-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$19.00K derived: sum of 2 quarters · filed 2023-11-13 | -$8.00K 10-Q · filed 2023-11-13 | -$4.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$7.00K 10-Q · filed 2023-08-10 | -$3.00K derived: sum of 3 quarters · filed 2023-08-10 | -$10.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $11.00K 10-Q · filed 2023-05-11 | $15.00K derived: sum of 2 quarters · filed 2023-05-11 | $8.00K derived: sum of 3 quarters · filed 2023-05-11 | -$21.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$3.00K derived: sum of 2 quarters · filed 2023-03-30 | -$32.00K derived: sum of 3 quarters · filed 2023-03-30 | -$13.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$36.00K derived: sum of 2 quarters · filed 2022-11-14 | -$17.00K 10-Q · filed 2022-11-14 | $78.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$29.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$10.00K 10-Q · filed 2022-08-10 | $85.00K derived: sum of 3 quarters · filed 2022-08-10 | $69.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $19.00K 10-Q · filed 2022-05-16 | $114.00K derived: sum of 2 quarters · filed 2022-05-16 | $98.00K derived: sum of 3 quarters · filed 2022-05-16 | $802.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $79.00K derived: sum of 2 quarters · filed 2022-03-31 | $783.00K derived: sum of 3 quarters · filed 2022-03-31 | $330.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | -$16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $688.00K derived: sum of 2 quarters · filed 2021-11-10 | $235.00K 10-Q · filed 2021-11-10 | $417.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $704.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $251.00K 10-Q · filed 2021-08-05 | $433.00K derived: sum of 3 quarters · filed 2021-08-05 | $240.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$453.00K 10-Q · filed 2021-05-06 | -$271.00K derived: sum of 2 quarters · filed 2021-05-06 | -$464.00K derived: sum of 3 quarters · filed 2021-05-06 | -$530.00K derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$11.00K derived: sum of 2 quarters · filed 2021-03-11 | -$77.00K derived: sum of 3 quarters · filed 2021-03-11 | $18.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | -$193.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$259.00K derived: sum of 2 quarters · filed 2020-11-05 | -$164.00K 10-Q · filed 2020-11-05 | -$300.00K derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | -$66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $29.00K 10-Q · filed 2020-08-06 | -$107.00K derived: sum of 3 quarters · filed 2020-08-06 | -$88.00K derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $95.00K 10-Q · filed 2020-05-08 | -$41.00K derived: sum of 2 quarters · filed 2020-05-08 | -$22.00K derived: sum of 3 quarters · filed 2020-05-08 | -$270.00K derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | -$136.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$117.00K derived: sum of 2 quarters · filed 2020-03-16 | -$365.00K derived: sum of 3 quarters · filed 2020-03-16 | -$373.00K 10-K · filed 2020-03-16 |
| 2018-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$229.00K derived: sum of 2 quarters · filed 2019-11-04 | -$237.00K 10-Q · filed 2019-11-04 | -$413.00K derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | -$248.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$256.00K 10-Q · filed 2019-08-08 | -$432.00K derived: sum of 3 quarters · filed 2019-08-08 | -$341.00K derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | -$8.00K 10-Q · filed 2019-05-09 | -$184.00K derived: sum of 2 quarters · filed 2019-05-09 | -$93.00K derived: sum of 3 quarters · filed 2019-05-09 | |
| 2017-12-31 | -$176.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$85.00K derived: sum of 2 quarters · filed 2019-03-14 | -$83.00K 10-K · filed 2019-03-14 | |
| 2017-09-30 | $91.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $93.00K 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $2.00K 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |